SiteOne's saxy synthesis

SiteOne synthesizing sodium channel inhibitors for non-narcotic pain relief

SiteOne Therapeutics Inc. is developing synthetic sodium channel blockers for pain that have a different chemical scaffold and better characterized binding site than competing molecules. The result, according to the company, should be advantages in potency, selectivity and solubility.

SiteOne's sodium channel platform is based on marine guanidinium toxins, which include tetrodotoxins, saxitoxins and gonyautoxins. These small molecules are used as pharmacological tools and have potent activity against voltage-gated sodium channels. The problem is that the difference between a therapeutic and a toxic dose of

Read the full 841 word article

How to gain access

Continue reading with a
two-week free trial.